Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Idera Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Idera Pharma Enters into Agreement with Pillar Partners Foundation 12
Idera Pharma Enters into Research Agreement with University of Texas 13
Licensing Agreements 14
Vivelix Pharma Enters into Licensing Agreement with Idera Pharma 14
GlaxoSmithKline Enters into Licensing Agreement with Idera Pharma 15
Equity Offering 16
Idera Pharma Prices Public Offering of Shares for USD50 Million 16
Idera Pharma Raises USD52.5 Million in Public Offering of Shares 18
Idera Pharma Raises USD86.3 Million in Public Offering of Shares 20
Idera Pharma Completes Public Offering Of Common Stock And Pre-Funded Warrants For US$40 Million 22
Idera Pharma Completes Public Offering Of Shares For US$27.7 Million 23
Idera Pharma Completes Public Offering Of Shares And Warrants For US$16.5 Million 25
Idera Pharma Completes Private Placement Of Preferred Shares For US$7 Million 27
Idera Pharmaceuticals Inc – Key Competitors 28
Idera Pharmaceuticals Inc – Key Employees 29
Idera Pharmaceuticals Inc – Locations And Subsidiaries 30
Head Office 30
Other Locations & Subsidiaries 30
Recent Developments 31
Financial Announcements 31
Aug 02, 2018: Idera Pharmaceuticals reports second quarter 2018 financial results and provides corporate update 31
May 09, 2018: Idera Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update 34
Mar 07, 2018: Idera Pharmaceuticals Reports Fourth Quarter and Year End 2017 Financial Results and Provides Corporate Update 36
Nov 06, 2017: Idera Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update 38
Aug 07, 2017: Idera Pharmaceuticals Reports Second Quarter 2017 Financial Results 41
May 04, 2017: Idera Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update 44
Mar 15, 2017: Idera Pharmaceuticals Reports Fourth Quarter and Year End 2016 Financial Results and Provides Corporate Update 47
Corporate Communications 50
Sep 18, 2018: Idera Pharmaceuticals names Howard Pien as Board Director 50
Apr 23, 2018: Kymera Appoints Industry Veteran Dr. Joanna Horobin to its Board of Directors 51
Oct 24, 2017: Idera Pharmaceuticals Provides Corporate Governance Update 52
Apr 18, 2017: Idera Pharmaceuticals Announces Organizational Update 53
Legal and Regulatory 54
Mar 23, 2018: Gainey McKenna & Egleston Announces They Have Filed A Class Action Lawsuit Against BioCryst Pharmaceuticals 54
Product News 55
11/09/2017: Idera Pharmaceuticals Presents Positive Translational and Clinical Data Update from Ongoing IMO-2125 Development Program at the 2017 Society for Immunotherapy of Cancer Annual Meeting (SITC) 55
04/11/2017: Idera Pharmaceuticals Advances Investigational Treatment – Intratumoral IMO-2125 in Combination with Ipilimumab – for Unmet Need in Anti-PD-1 Refractory Metastatic Melanoma 57
02/06/2017: Idera Announces Appointment of Jonathan Yingling, Ph.D. as Senior Vice President of Early Development 59
Product Approvals 60
Nov 29, 2017: U.S. FDA Grants Fast Track Designation for Idera Pharmaceuticals’ IMO-2125 in Combination with Ipilimumab for Treatment of PD-1 Refractory Metastatic Melanoma 60
Jun 22, 2017: Idera Announces FDA Orphan Drug Designation for IMO-2125 for the Treatment of Melanoma 61
Clinical Trials 63
Jun 04, 2018: Idera Pharmaceuticals Presents Clinical Data from the ILLUMINATE-204 Trial of the Combination of tilsotolimod and ipilimumab for Anti-PD-1 Refractory Metastatic Melanoma at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting 63
Apr 26, 2018: Idera Pharmaceuticals Announces Acceptance of Several Abstracts related to the ILLUMINATE Tilsotolimod Clinical Development Program at the American Society of Clinical Oncology (ASCO) Meeting 65
Apr 17, 2018: Idera Pharmaceuticals Presents Pre-Clinical Data Demonstrating Potential for Tilsotolimod (IMO-2125) in Combination with Checkpoint Inhibitors at the American Association for Cancer Research (AACR) 2018 Annual Meeting 67
Mar 01, 2018: Idera Pharmaceuticals Announces Launch of Global Phase 3 Trial Evaluating IMO-2125 in Combination with Ipilimumab for the Treatment of Anti-PD-1 Refractory Melanoma (ILLUMINATE 301) 68
Sep 10, 2017: Idera Pharmaceuticals Presents Positive Phase 1 Data for Intratumoral IMO-2125 in Combination with Ipilimumab Demonstrating an Overall Response Rate of 44% in Melanoma Patients Refractory to Anti-PD1 Therapy 69
Sep 08, 2017: Idera Pharmaceuticals Presents Pre-Clinical Data from IMO-2125 Treatment in Combination with Ipilimumab that Demonstrates Induction of Durable Anti-tumor Responses Associated with Tumor-Specific Memory 71
Apr 05, 2017: Idera Pharmaceuticals Presents Clinical Translational and Pre-Clinical Data from IMO-2125 Development Program at the American Association for Cancer Research (AACR) 2017 Annual Meeting 72
Feb 24, 2017: Idera Pharmaceuticals Presents Update from Ongoing Phase 1 Dose Escalation Clinical Trial of Intratumoral IMO-2125 in Combination with Ipilimumab in Metastatic Melanoma Patients Refractory to Anti-PD-1 Treatment at the 2017 ASCO-SITC Clinical Immuno-Oncology Symposium 74
Other Significant Developments 75
Jul 16, 2018: Idera Pharmaceuticals Provides Update on Corporate Strategy and Outlook 75
Jan 05, 2018: Idera Pharmaceuticals Provides 2018 Update and Outlook 77
Appendix 79
Methodology 79
About GlobalData 79
Contact Us 79
Disclaimer 79
Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Idera Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Idera Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10
Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Idera Pharma Enters into Agreement with Pillar Partners Foundation 12
Idera Pharma Enters into Research Agreement with University of Texas 13
Vivelix Pharma Enters into Licensing Agreement with Idera Pharma 14
GlaxoSmithKline Enters into Licensing Agreement with Idera Pharma 15
Idera Pharma Prices Public Offering of Shares for USD50 Million 16
Idera Pharma Raises USD52.5 Million in Public Offering of Shares 18
Idera Pharma Raises USD86.3 Million in Public Offering of Shares 20
Idera Pharma Completes Public Offering Of Common Stock And Pre-Funded Warrants For US$40 Million 22
Idera Pharma Completes Public Offering Of Shares For US$27.7 Million 23
Idera Pharma Completes Public Offering Of Shares And Warrants For US$16.5 Million 25
Idera Pharma Completes Private Placement Of Preferred Shares For US$7 Million 27
Idera Pharmaceuticals Inc, Key Competitors 28
Idera Pharmaceuticals Inc, Key Employees 29
Idera Pharmaceuticals Inc, Other Locations 30
List of Figures
Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Idera Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Idera Pharmaceuticals Inc, Medical Devices Deals, 2012 to YTD 2018 10